Literature DB >> 21792045

Survival outcome of childhood acute lymphoblastic leukemia in India: a resource-limited perspective of more than 40 years.

Ketan Prasad Kulkarni1, Ramandeep Singh Arora, Ram Kumar Marwaha.   

Abstract

The outcome of childhood acute lymphoblastic leukemia in India has been inferior to more than 80% cure rates in developed nations. This study was done to analyze the outcome of acute lymphoblastic leukemia in India over 4 decades. There has been a gradual improvement in survival rates of up to >70% in some centers along with a decline in relapse and mortality. However, these results cannot be generalized to the entire nation. There is a crying need to address treatment abandonment, take quality improvement, educational and financial initiatives; cooperative research into risk factors and disease biology, and the implementation of risk stratification along with the assessment of response to therapy.

Entities:  

Mesh:

Year:  2011        PMID: 21792045     DOI: 10.1097/MPH.0b013e31820e7361

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  17 in total

Review 1.  Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.

Authors:  Allen E J Yeoh; Daryl Tan; Chi-Kong Li; Hiroki Hori; Eric Tse; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2013-11       Impact factor: 41.316

2.  Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol.

Authors:  Akhil Rajendra; Hasmukh Jain; V N Avinash Bonda; Lingaraj Nayak; Prashant Tembhare; Dhanlaxmi Shetty; Jayashree Thorat; Hemani Jain; Papagudi Ganesan Subramanian; Nikhil Patkar; Gaurav Chatterjee; Navin Khattry; Anant Gokarn; Sachin Punatar; Smruti Mokal; Bhausaheb Bagal; Manju Sengar
Journal:  Blood Adv       Date:  2021-03-09

Review 3.  Outcome of neuroblastoma in India.

Authors:  Ketan Prasad Kulkarni; Ram Kumar Marwaha
Journal:  Indian J Pediatr       Date:  2013-01-23       Impact factor: 1.967

4.  High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.

Authors:  Zafar Iqbal; Tanveer Akhtar; Tashfin Awan; Aamer Aleem; Noreen Sabir; Mahmood Rasool; Muhammad Absar; Afia M Akram; Masood A Shammas; Ijaz H Shah; Muhammad Khalid; Abid S Taj; Abid Jameel; Abdullah Alanazi; Ammara T Gill; Jamil Amjad Hashmi; Akhtar Hussain; Muhammad Farooq Sabar; Ahmad M Khalid; Mehmood Hussain Qazi; Sajjad Karim; Muhammad Hassan Siddiqi; Aamir Mahmood; Mudassar Iqbal; Anjum Saeed; Muhammad Imran Irfan
Journal:  Mol Diagn Ther       Date:  2015-10       Impact factor: 4.074

Review 5.  Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Authors:  Sunitha Kodidela; Pradhan Suresh Chandra; Biswajit Dubashi
Journal:  Eur J Clin Pharmacol       Date:  2013-12-27       Impact factor: 2.953

6.  Perception and attitudes versus medical writing skills.

Authors:  P M Parikh
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun

Review 7.  Acute leukemia in children: A review of the current Indian data.

Authors:  Ramandeep Singh Arora; Brijesh Arora
Journal:  South Asian J Cancer       Date:  2016 Jul-Sep

8.  Determinants of Treatment Abandonment in Childhood Cancer: Results from a Global Survey.

Authors:  Paola Friedrich; Catherine G Lam; Geetinder Kaur; Elena Itriago; Raul C Ribeiro; Ramandeep S Arora
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

9.  L-Asparaginase induced thrombosis in acute lymphoblastic leukemia.

Authors:  Ketan P Kulkarni
Journal:  J Pharmacol Pharmacother       Date:  2012-07

10.  Symptom diagnosis interval in childhood acute lymphoblastic leukemia: Prognostic impact and association with clinico-demographic factors.

Authors:  Ketan P Kulkarni; Ram K Marwaha
Journal:  Indian J Med Paediatr Oncol       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.